Soumi Acharya, S. S. Meenambiga
Soumi Acharya, S. S. Meenambiga*
Department of Bio-Engineering, School of Engineering, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Chennai - 600117, Tamilnadu, India.
Volume - 13,
Issue - 4,
Year - 2020
Parkinson's Disease is considered as a neurodegenerative disorder and is identified by the deterioration of the motor functions due to loss of the dopamine releasing neurons. Due to this dementia occurs which is characterised by forgetfulness and impairment in cognitive abilities. The effectiveness, cellular penetration and transport of drugs to the target organs, tissues or cells is the main hindrance in the diagnosis and the treatment of this disorder. The main obstacle in the drug delivery system is the presence of blood brain barrier which checks the penetration of drugs and causes side effects. Nanoparticle eases the drug delivery to the central nervous system via blood brain barrier against the conventional drug delivery. Nanotechnology interact at a molecular level with the biological system and revolutionize the treatment by stimulating, responding to, and interacting with target sites to induce physiological responses while minimizing side effects. This review focuses on current applications of nanomaterials in the therapy and diagnosis of the most common neurodegenerative disorder and highlights the future nanotechnological approaches.
Cite this article:
Soumi Acharya, S. S. Meenambiga. Nanotechnology in Parkinson's Disease - A Review. Research J. Pharm. and Tech. 2020; 13(4):1965-1969. doi: 10.5958/0974-360X.2020.00354.6
Soumi Acharya, S. S. Meenambiga. Nanotechnology in Parkinson's Disease - A Review. Research J. Pharm. and Tech. 2020; 13(4):1965-1969. doi: 10.5958/0974-360X.2020.00354.6 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-4-64
1. Jayaraj R, Chandramohan VI, Namasivayam EL. Nanomedicine for Parkinson disease: Current status and future perspective. Int. J. Pharm. Bio. Sci. 2013;4:692.
2. Yvette Brazier. Parkinson's disease and its causes. Available from: URL: https://www.medicalnewstoday.com/articles /323396.php. October 2018
3. Yvette Brazier. Treatment options for Parkinson’s Disease. Available from: URL: https://www.medicalnewstoday.com/articles/323462.php. October 2018
4. Carl Nierenberg. Parkinson’s Disease: Risks, Symptoms and Treatment. Available from: URL: https://www.livescience. com/65123-parkinsons-disease.html. April 2019.
5. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991 Oct 1;114(5):2283-301.
6. Kimberly Holland. Everything You Want to Know About Parkinson’s disease. Available from: URL: https://www. healthline.com/health/parkinsons. January 2019.
7. Kaushik AC, Bharadwaj S, Kumar S, Wei DQ. Nano-particle mediated inhibition of Parkinson’s disease using computational biology approach. Scientific reports. 2018 Jun 15;8(1):9169.
8. Medlineplus, NIH U.S. National Library of Medicine, Parkinson's Disease, also called: Paralysis agitans, Shaking palsy. Available from: URL: https://medlineplus.gov/parkinsonsdisease.html
9. JamieEske.13 Early Signs Of Parkinson’s Disease. Available from: URL:https://www.medicalnewstoday.com/articles/324087. phpJanuary 2019.
10. Modi G, Pillay V, Choonara YE. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Annals of the New York Academy of Sciences. 2010 Jan 1;1184(1):154-72.
11. Zhang W, Wang W, Yu DX, Xiao Z, He Z. Application of nanodiagnostics and nanotherapy to CNS diseases. Nanomedicine. 2018 May 9;13(18):2341-71.
12. Gourie-Devi M, Ramu MG, Venkataram BS. Treatment of Parkinson's disease in ‘Ayurveda’(ancient Indian system of medicine): discussion paper. Journal of the Royal Society of Medicine. 1991 Aug;84(8):491-2.
13. Brundin P, Wyse R. Cancer enzyme affects Parkinson's disease. Science. 2018 Nov 2;362(6414):521-2.
14. Korczyn AD. Drug treatment of Parkinson's disease. Dialogues Clin Neurosci. 2004;6(3):315–322.
15. Lee DJ, Lozano AM. The Future of Surgical Treatments for Parkinson’s Disease. Journal of Parkinson's disease. 2018 Jan 1;8(s1):S79-83.
16. Adhikary RR, Sandbhor P, Banerjee R. Nanotechnology platforms in Parkinson’s Disease. ADMET and DMPK. 2015 Sep 5;3(3):155-81.
17. Pahuja R, Seth K, Shukla A, Shukla RK, Bhatnagar P, Chauhan LK, Saxena PN, Arun J, Chaudhari BP, Patel DK, Singh SP. Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats. ACS nano. 2015 Apr 22;9(5):4850-71.
18. Barcia E, Boeva L, García-García L, Slowing K, Fernández-Carballido A, Casanova Y, Negro S. Nanotechnology-based drug delivery of ropinirole for Parkinson’s disease. Drug delivery. 2017 Jan 1;24(1):1112-23.
19. Kulkarni AD, Vanjari YH, Sancheti KH, Belgamwar VS, Surana SJ, Pardeshi CV. Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review. Journal of drug targeting. 2015 Oct 21;23(9):775-88.
20. Hu K, Chen X, Chen W, Zhang L, Li J, Ye J, Zhang Y, Zhang L, Li CH, Yin L, Guan YQ. Neuroprotective effect of gold nanoparticles composites in Parkinson's disease model. Nanomedicine: Nanotechnology, Biology and Medicine. 2018 Jun 1;14(4):1123-36.
21. Alice Melao. June 20 2018.Cerium Oxide Nanoparticles Hold Therapeutic Potential For Parkinson's Study Finds.
22. Bharali DJ, Klejbor I, Stachowiak EK, Dutta P, Roy I, Kaur N, Bergey EJ, Prasad PN, Stachowiak MK. Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. Proceedings of the National Academy of Sciences. 2005 Aug 9;102(32):11539-44.
23. Cortes H, Alcalá-Alcalá S, Ávalos-Fuentes A, Mendoza-Muñoz N, Quintanar-Guerrero D, Leyva-Gomez G, Florán B. Nanotechnology As Potential Tool for siRNA Delivery in Parkinson's Disease. Current drug targets. 2017 Dec 1;18 (16):1866-79.
24. Emily Aries, Kathryn Lee, Catherine Scrace. Applications of Nanotechnology in the Diagnosis and Treatment of Parkinson’s disease. MedLink 2010;
25. Yue HY, Huang S, Chang J, Heo C, Yao F, Adhikari S, Gunes F, Liu LC, Lee TH, Oh ES, Li B. ZnO nanowire arrays on 3D hierachical graphene foam: biomarker detection of Parkinson’s disease. ACS nano. 2014 Jan 13;8(2):1639-46.